-
GSK Plc (NYSE: GSK) has agreed to acquire the late-stage biopharmaceutical company BELLUS Health Inc (NASDAQ: BLU) for $14.75 a share in money, representing a complete equity value of around $2.0 billion (£1.6 billion).
-
The pharmaceutical giant said the deal would offer access to camlipixant, a treatment for refractory chronic cough in phase 3 development.
-
Following the anticipated regulatory approval and launch of camlipixant in 2026, the corporate’s acquisition is predicted to be accretive to adjusted earnings per share from 2027 and potentially deliver significant sales through 2031 and beyond.
-
“This proposed acquisition complements our portfolio of specialty medicines and builds on our expertise in respiratory therapies,” Chief Industrial Officer Luke Miels said.
-
“The acquisition of BELLUS is very synergistic with GSK’s expertise in respiratory medicines and is further supported by GSK’s leading R&D, manufacturing, and commercialization capabilities,” he added.
-
In December 2021, BELLUS announced data from the SOOTHE phase 2b trial, indicating that it met its primary endpoint for the 50 mg and 200 mg twice-daily doses.
-
Based on these data, BELLUS initiated the CALM phase 3 development program consisting of the CALM-1 and CALM-2 trials, with data anticipated in H2 2024 and 2025, respectively.
-
BELLUS announced data from a Phase 1 study evaluating QD (once-daily) formulation for camlipixant.
-
The once-daily extended-release formulation demonstrated equivalent bioavailability to the twice-daily immediate-release formulation.
-
The extended-release formulation was well tolerated, and no taste-related antagonistic events were reported.
-
Price Motion: BLU shares are up 97.7% at $14.35 in the course of the premarket session on the last check Tuesday.
Don’t miss real-time alerts in your stocks – join Benzinga Pro free of charge! Try the tool that may assist you invest smarter, faster, and higher.
This text GSK To Strengthen Specialty Medicines and Respiratory Pipeline With $2B BELLUS Health Acquisition originally appeared on Benzinga.com
.
© 2023 Benzinga.com. Benzinga doesn’t provide investment advice. All rights reserved.